Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RNDO-564 Monotherapy and Combination With Pembrolizumab in Advanced Solid Tumors
NCT07218003Phase 1Enrolling by invitation
- Sponsor
- Rondo Therapeutics
- Start
- Nov 2025
- Primary completion
- Feb 2029
- Modality
- Prophylactic Vaccines, Bispecific Antibodies, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of RNDO-564 in urothelial carcinoma (UC), non-small cell lung cancer (NSCLC), Cervical Cancer (CC) and 5 more (15 arms), sponsored by Rondo Therapeutics. Primary endpoints: Adverse Events and Recommended Phase 2 Dose. Started Nov 2025; status: enrolling by invitation.
02
Drugs
RNDO-564
03
Conditions
urothelial carcinoma (UC)non-small cell lung cancer (NSCLC)Cervical Cancer (CC)head and neck squamous cell carcinoma (HNSCC)esophageal cancer
Beyond the preview
Go deeper on NCT07218003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07218003.